Navigation Links
ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
Date:7/6/2011

MOUNT LAUREL, N.J., July 6, 2011 /PRNewswire/ -- ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, offers pharmaceutical brand managers unique insight into the effectiveness of their direct-to-consumer promotional efforts.  ImpactRx's proprietary database, ImpactData™, annually captures more than 250,000 brand requests by patients.   ImpactRx then records physicians' treatment behavior in response to these requests from their patients.

ImpactRx's longitudinal research model provides information on changes in patient request trends over time.  Through the ImpactData, the effectiveness of a brand's DTC campaign can be quickly measured by the change in share of patient requests generated before and after the campaign's initiation.

Additionally, ImpactRx uniquely tracks how often physicians honor requests from their patients across all therapeutic areas.  The ImpactData documents that patient requests underlie a greater proportion of physician usage of lifestyle drugs for the treatment of conditions such as erectile dysfunction and smoking cessation than usage of medications for chronic conditions like high cholesterol or diabetes.  More than 20% of lifestyle treatments are associated with a patient request, while less than 5% of chronic medications have a corresponding request.  Physician fulfillment rates per patient request, however, are similar for most therapeutic areas.  Adding sample usage by physicians to their prescription writing increases the overall average fulfillment rate per request to about 85%.

Lesley Bailey, Senior Director, Product Development/Marketing at ImpactRx, stated, "although there are differences in degree across markets, our data clearly shows that patient requests influence physician behavior.  The longitudinal nature of our research model coupled with its physician-level linkage from request through to fulfillment, enables us to provide our clients unique insight into the effectiveness of their DTC campaigns," Bailey continued.  "To get a true read on the impact of their DTC efforts, our clients need to know not only if they are generating requests for their brands, but also if physicians are honoring those requests," said Bailey.

"The effectiveness of Uloric's recent DTC activity in the gout market is something we're watching closely," stated Bailey.  "Patients are requesting Uloric at higher-than-average rates, so the ultimate success of the brand's campaign will hinge on its ability to educate physicians to fulfill those requests," Bailey finished.

ImpactRx's panels span fourteen specialties including Primary Care, Oncology, Endocrinology, Cardiology, Rheumatology and Neurology.  New panels supporting Pulmonology and Adult Psychiatry were launched earlier this year.

About ImpactRx

Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx's longitudinal panels of high value, iPhone-connected physicians are the exclusive source of continuously-captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx is a private company with investment financing provided by Symphony Technology Group (www.symphonytg.com) and Merck Capital Ventures.  For more information, visit: www.impactrx.com.

CONTACT:  
Lesley Bailey
Senior Director, Product Development/Marketing
ImpactRx, Inc.
856-802-4133
lbailey@impactrx.com


'/>"/>
SOURCE ImpactRx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
3. ImpactRx Releases 2010 Oncology Promotion Report
4. ImpactRx Acquired by Symphony Technology Group
5. ImpactRx Expands Psychiatry Research Panel to Include Adolescent Psychiatrists
6. ImpactRx Names Kjell Nygren Vice President, Analytical Services
7. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
8. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
9. ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
10. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
11. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):